One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™
Launched by VIACYTE · Oct 18, 2016
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Previous implantation of VC-01™ combination product with subsequent explantation of all VC-01 units.
- Exclusion Criteria:
- • There are no exclusion criteria for this trial.
About Viacyte
ViaCyte is a pioneering biotechnology company focused on the development of innovative cell-based therapies for the treatment of diabetes. By harnessing the potential of stem cell-derived pancreatic islet cells, ViaCyte aims to restore the body’s ability to produce insulin, thus addressing the underlying causes of the disease. The company is dedicated to advancing its research through rigorous clinical trials and collaborations, driven by a commitment to improving patient outcomes and transforming diabetes care. With a team of experienced professionals, ViaCyte strives to bring novel therapeutic solutions to market, enhancing the quality of life for individuals living with diabetes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials